Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies
{{output}}
Introduction: From the 1960s and up until 2021, neoadjuvant chemotherapy has represented the standard of care for potentially resectable stage III (N2) Non-Small Cell Lung Cancer (NSCLC). However, in recent years, immunotherapy i... ...
